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Glycine reduces early renal parenchymal uptake of cisplatin. We
evaluated the effect of glycine infusions on the early renal uptake of
cisplatin, measured one hour after cisplatin was injected, as well as five
days following cisplatin administration. Glycine (1.25 mmol per 100 g
body wt) markedly attenuated the early uptake of platinum by the
kidney, an effect not observed with control infusions of saline or of
L-alanine. The kidney content of platinum at five days, on the other
hand, was similar in glycine-treated animals and saline controls. Ear'y
inhibition of renal uptake of platinum may be responsible for glycine's
protective action in experimental cisplatin nephrotoxicity.
Reports of the cytoprotective effect of glycine, alanine, and
structurally related compounds from hypoxic and toxic insults
in vitro [1—7] have recently been extended to cisplatin nephro-
toxicity in vivo [8]. Glycine infusion (75 mg/kg/hr) markedly
attenuated the proximal (S3) tubular injury and deterioration of
renal function seen five days after the administration of cisplatin
(3.5 or 5 mg/kg). Similar protection was not afforded by
infusions of L-alanine [8]. This finding is of clinical interest,
since nephrotoxicity remains the major adverse effect of cis-
platin chemotherapy, in spite of various protective measures
[91.
Although glycine-related cytopreservation has been studied
extensively [10—14], its mechanism still remains unclear. Phys-
iological concentrations of glycine (0.25 to 2 mM) appear to
blunt hypoxic and toxic tubular damage in vitro [1—8, 11, 13—15],
but cytoprotection in vivo has been more difficult to demon-
strate. Much higher plasma levels induced at the time of the
injection of cisplatin (3.5 to 8 mM) were required to prevent
cisplatin nephrotoxicity in intact rats [8]. Moreover, this finding
was anomalous, since comparable glycine infusions failed to
modify renal injury produced in vis'o by ischemia-reflow or
radiocontrast injection [16]. The cytoprotection observed with
glycine in vitro, in isolated cells or perfused organs, might
reflect replenishment of cellular stores of glycine that are
normally present during life but are depleted in the course of
organ perfusion with artificial media or the preparation of
isolated tubules and cells [151. We wondered if glycine infusions
in intact rats might modify the early uptake of cisplatin by the
kidney, thereby blunting its toxic effect. Though glycine did not
affect early urinary and plasma contents of platinum or platinum
levels in kidneys measured five days after injection [8], we now
report that the infusion of glycine markedly attenuates early
accumulation of platinum in the kidney, suggesting a mecha-
nism for glycine's protective effect.
Methods
In vivo studies
General. Male Sprague-Dawley rats (210 to 330 g) were used
for all experiments. They were given regular chow and tap
water ad libitum. Under mactin anesthesia (100 mg/kg) the right
jugular vein was cannulated with two polyethylene tubes (PE-
50, Clay-Adams, Parsippany, New Jersey, USA) for the infu-
sion of cisplatin and amino acids. The bladder was cannulated
by a polyethylene tube for urine collection as previously
described [171, and the rats were kept in heated chambers
(37°C) throughout the experiment. At the end of the infusion
period the rats were sacrificed and plasma, red blood cells and
tissue samples from kidney, liver and gut were obtained for the
determination of platinum content. In another set of experi-
ments rats were anesthetized with phenobarbital (65 mg/kg) and
their bladders were not cannulated. At the end of the infusion
period, the venous cannulae were removed, the rats were
allowed to recover and were sacrificed five days later for the
determination of organ platinum contents.
Cisplatin injection. Five mg/kg cisplatin were injected over 60
seconds through a jugular cannula. A preparation used in
clinical practice was utilized (Platinol, Bristol-Myers Co.,
Evansville, Indiana, USA), dissolved in distilled water, each
milliliter containing 1.67 mg cisplatin, 16.7 mg of mannitol and
15 mg of sodium chloride.
Amino acid infusion. Glycine was infused at a rate of 75 mg
(1 mmol) per 100 g body wt, in 1.06 ml saline per hour.
L-alanine was given in an equimolar dose (89 mg/100 g body
wt/l .56 ml saline/hr). The lower solubility of alanine necessi-
tated the difference in solute volume. Control rats were given
1.06 ml saline/hr.
The infusion of glycine, alanine, or saline was initiated
through the second cannula 15 minutes before the cisplatin
injection and was carried out for 75 minutes.
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Cisplatin measurement
Heparinized blood samples were centrifuged to obtain plasma
and erythrocytes. The entire right kidney and samples of tissue
obtained from liver and gut were weighed. All specimens were
1226
Heyman et al: Cisplatin uptake 1227
Table 1. Platinum content of organs, red blood cells, plasma and urine
.
Experimental
group N
Plasma
gIm1
RBC Kidney Liver Gut .Urine
p.g/gww j,g/hr
Controls 9
4
60 mm
5 days
1.03 0.06
0.12 0.01
1.7 0.2
1.6 0.1
9.2 0.5
6.0 0,2b
3,2 0.2
1.7 0.1
1.1 0.0
0.5 0.1
327 25
Glycine 9
4
60 mm
5 days
0.98 0.10
0.09 0.Ola
1.5 0.2
1.4 0.2
5.6 0.2°
5.4 0.P
3.1 0.2
1.6 0.1
1.2 0.1
0.5 0.0
391 45
Alanine 4 60 mm 1.5 0.29(N=5) 11.2 2.2
348 41
a P < 0.05 vs. control, 5 days (Student's t-test)
b P < 0.002 vs. 60 mm (Student's t-test); N = 8 for kidney platinum content in rats given glycine
° P < 0.05 vs. others at 60 mm (ANOVA)
then immediately frozen (—20°C) and analyzed later in duplicate
for platinum levels with a Perkin Elmer model 1100 atomic
absorption spectrometer, as described elsewhere [18].
Statistics
Values are presented as the means SE. Non-paired Stu-
dent's t-test and one-way analysis of variance with the Newman
Keuls test were applied for the comparisons of platinum con-
tent. Statistical significance was set at P < 0.05.
Results
Table 1 summarizes the results of platinum contents in
tissues, blood components and urine in the various experimen-
tal groups. Sixty minutes after the injection of cisplatin, the
platinum contents of plasma, red cells, liver and gut were
comparable in rats treated with glycine and with saline. By
contrast, kidney platinum content was markedly lower in rats
given glycine than in saline-infused controls (5.6 0.2 vs. 9.2
0.5 g/g wet weight; P < 0.01, ANOVA), or in rats infused with
alanine (11.2 2.2 xg/g wet weight). Urinary excretion of
cisplatin was not significantly different among the three groups.
In Figure 1, urinary excretion of platinum during the first hour
is plotted against the kidney content of platinum at the end of
that time. At comparable rates of platinum excretion, the
kidneys of glycine-treated rats uniformly contained less plati-
num than the kidneys of control rats given saline.
Five days later, plasma platinum levels were slightly lower in
the glycine group, as compared to controls (0.09 0.2 vs. 0.12
0.01 ig/m1, P = 0.04, Students' t-test), in concert with our
previous report, probably because renal excretory function is
better preserved in glycine-treated animals, permitting more
platinum to be excreted [8]. Platinum contents of liver, gut, and
red cells were unaffected by glycine. Kidney platinum was
slightly lower in the glycine group after five days, as compared
to controls (5.4 0.1 vs. 6.0 0.2 tgIgww, P = 0.03), but
whereas it fell by some 35% from the first to the fifth day in
controls (P < 0.002), it remained unchanged in rats treated with
glycine.
Discussion
High plasma and parenchymal levels of glycine are required
for renal salvage at the time of injection of cisplatin, since
delayed glycine infusion is not protective [8]. As toxic intracel-
lular platinum species are probably formed early after injection
and quickly converted to inactive forms [19], early, rather than
late tissue platinum content may better predict cellular damage.
•. •• •
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Fig. 1. Urinary excretion of platinum is plotted against kidney content
of platinum at the end of one hour following cisplatin infusion in rats
treated with glycine (S) or saline (0). At comparable rates of platinum
excretion, the kidneys of glycine-treated rats accumulated less platinum
than those of saline-treated rats.
In this perspective, the low kidney platinum content observed
in glycine-treated rats shortly after injection of cisplatin may
explain the protective effect of glycine. It is notable that
although the early (1 hr) kidney content of platinum was almost
halved by glycine, plasma levels of platinum and urinary
excretion of platinum were not significantly different from those
of control rats given saline. In contrast, L-alanine did not
reduce the early platinum content of the kidney, and was not
protective [8]. The effect of glycine on the platinum content of
the kidney was specific in that levels of platinum in other organs
(liver and gut) were unaffected by glycine. After five days, the
platinum content of the kidney in glycine-treated rats was only
marginally lower than in control animals given saline, presum-
ably reflecting the delayed accumulation of non-toxic platinum
species as glycine levels in the plasma fell to their physiological
range. In vitro studies of cytoprotection by glycine have con-
sistently shown that the amino acid must be present at the time
that cells would otherwise undergo lethal membrane damage.
Since cell necrosis is not seen for 24 to 48 hours after cisplatin
administration, it is likely that if glycine is provided only at the
time cisplatin is initially administered, its cytoprotective effect
is achieved by acting on an earlier event such as the uptake or
activation of cisplatin, as suggested by these experiments.
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Experimental cisplatin nephrotoxicity can be blunted by
prehydration, saline diuresis, or treatment with furosemide,
mannitol and other diuretics which, however, do not lower the
plasma level or renal content of platinum [19]. The present
experiments suggest that inhibition of the renal uptake of
platinum might also be useful in preventing renal injury from
cisplatin. Cisplatinum is actively transported into cells lining
the straight portion of the proximal tubule (S3), leading to
accumulation that is most marked in the region of the corti-
comedullary junction. The selective early uptake of cisplatin by
these cells presumably accounts for the sharply specific local-
ization of early cisplatin toxicity to S3 segments in the outer
medulla and medullary rays [19]. The mechanism of uptake
across the basolateral border probably involves the organic
cation transporter responsible for secretion of an array of
positively-charged substituted nitrogenous bases. Accumula-
tion of cisplatin by kidney slices is inhibited by drugs that
specifically block this transport pathway, like tolazoline and
mepiperphenidol [201. The inhibitors of organic cation trans-
port, quinine and cyanine, protect against cisplatin nephrotox-
icity when infused into the renal portal circulation of chickens
[21]. While glycine is also actively transported by renal cells
[22—24], it is not known whether it utilizes the organic cation
transporter. The present findings suggest the possibility that
glycine might interfere with cisplatin uptake by renal tubular
cells in the S3 segment, perhaps by affecting a cation trans-
porter.
In summary, glycine infusions markedly reduce early renal
accumulation of cisplatin. This may explain their amelioration
of cisplatin nephrotoxicity.
Reprint requests to Franklin H. Epstein, M.D., Renal Division,
Harvard Medical School, 330 Brookline Avenue, Boston, Massachu-
setts 02215, USA.
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